AP-SA02 / Armata - LARVOL DELTA

diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects with S. Aureus Bacteremia (clinicaltrials.gov) - P1/2 | N=50 | Completed | Sponsor: Armata Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PRNewswire) - "Armata Pharmaceuticals...announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva..., Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses. Proceeds from the new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively....'This financing will enable Armata to readout its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia, which represents the first clinical trial for AP-SA02, and to prepare the Company for an end-of-Phase 2 meeting with the FDA in support of further clinical inquiry including a potential pivotal trial'."

Financing • Infectious Disease

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium (PRNewswire) - "Armata Pharmaceuticals...will deliver a poster presentation at the 2024 Military Health System Research Symposium (MHSRS), which is being held August 26-29 in Kissimmee, FL....The poster provides an overview of Armata's two distinct phage development programs, inhaled AP-PA02 (Pseudomonas aeruginosa bronchiectasis) and intravenous AP-SA02 (Staphylococcus aureus (S. aureus) bacteremia), which are being or have been evaluated in three distinct double-blind, placebo-controlled Phase 2 clinical trials.... Enrollment of the diSArm study is 80% complete, and Armata anticipates completing enrollment by the end of 2024....We look forward to advancing both AP-SA02 and AP-PA02 into pivotal Phase 3 trials next year with the hope of introducing a distinct new class of anti-infectives to patient care....Promising data for both phage candidates is expected to be utilized for planning pivotal Phase 3 clinical trials in 2025."

Enrollment status • New P3 trial • P2 data • P3 data • Bronchiectasis • Infectious Disease

diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: Armata Pharmaceuticals, Inc. | Phase classification: P1b/2a ➔ P1/2 | Trial completion date: Dec 2023 ➔ Mar 2025 | Trial primary completion date: Sep 2023 ➔ Dec 2024

Phase classification • Trial completion date • Trial primary completion date

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update (PRNewswire) - "Second Quarter 2022 and Recent Developments: Phase 2 Tailwind study of AP-PA02 in non-CF bronchiectasis (NCFB) initiated....The Company recognized grant revenue of approximately $1.9 million for the three months ended June 30, 2022, which represents Medical Technology Enterprise Consortium's ('MTEC') share of the costs incurred for the Company's AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $15.0 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program."

Financing • Trial status • Bronchiectasis • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis

diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (clinicaltrials.gov) - P1b/2a | N=50 | Recruiting | Sponsor: Armata Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open